Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Health-Related Quality of Life (HRQL) Trajectories during Treatment for Advanced Stage Pediatric Hodgkin Lymphoma (HL)

Susan K Parsons, MD MRP, Angie Mae Rodday, PhD MS, Rizvan Bush, MS, Qinglin Pei, PhD, Anem Waheed, MD MPH, Frank G Keller, MD, Kara M. Kelly, MD, Tara O. Henderson, MD MPH, Sharon M. Castellino, MD MSc

Blood (2018) 132 (Supplement 1): 3587.

https://doi.org/10.1182/blood-2018-99-112664

Published: 2018

Journal Articles

Carfilzomib Weekly 20/56mg/m², Lenalidomide and Dexamethasone for Early Relapsed Refractory Multiple Myeloma

Blood (2018) 132 (Supplement 1): 3276.

https://doi.org/10.1182/blood-2018-99-111934

Published: 2018

Journal Articles

Comparison of Outcome of Adolescents with Newly Diagnosed Hodgkin Lymphoma (HL) in Argentina, Treated within a Pediatric Vs an Adults Clinical Trial : Experience of the Gatla Group

David Alejandro Veron, MD, Patricia Streitenberger, MD, Daniel Freigeiro, MD, Astrid Pavlovsky, MD

Blood (2017) 130 (Supplement 1): 5175.

https://doi.org/10.1182/blood.V130.Suppl_1.5175.5175

Published: 2017

Journal Articles

Long Term Follow-up of Adults with Burkitt's Lymphoma Receiving Dose-Dense Chemotherapy with or without Rituximab: A Single Center Retrospective 20 Years Study of 51 Patients

Benjamin Bouchacourt, Christophe Zemmour, Diane Coso, Catalina Montes de Oca, Lenaig Mescam, Sylvain Garciaz, Jean Marc Schiano de Collela, Anne-Marie Stoppa, MD, Didier Blaise, Reda Bouabdallah, MD

Blood (2017) 130 (Supplement 1): 5240.

https://doi.org/10.1182/blood.V130.Suppl_1.5240.5240

Published: 2017

Journal Articles

The Treatment of Primary Mediastinal Large B-Cell Lymphoma: A Two Decades Monocentric Experience on 98 Patients

Beatrice Casadei, MD, Alessandro Broccoli, MD, Vittorio Stefoni, MD, Cinzia Pellegrini, Letizia Gandolfi, MD, Enrico Derenzini, MD, Federica Quirini, MD, Lisa Argnani, PhD, Pier Luigi Zinzani, MD, PhD

Blood (2014) 124 (21): 4440.

https://doi.org/10.1182/blood.V124.21.4440.4440

Published: 2014

Journal Articles

Impact Of Bone Marrow Involvement On Outcome Of Young Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL) Treated In The Phase III Randomized Trial (DLCL04) With Rituximab Dose-Dense Chemotherapy Followed By Intensified High-Dose Chemotherapy and Autologous Stem Cell Transplantation (HDC+ASCT) Or Standard Rituximab Dose Dense Chemotherapy: A Study of The Fondazione Italiana Linfomi (FIL)

Blood (2013) 122 (21): 4340.

https://doi.org/10.1182/blood.V122.21.4340.4340

Published: 2013

Journal Articles

High Efficacy and Significantly Shortened Neutropenia Of Dose-Dense S-HAM As Compared To Standard Double Induction: First Results Of a Prospective Randomized Trial (AML-CG 2008)

Jan Braess, MD, Karl-Anton Kreuzer, Karsten Spiekermann, PhD, Hans Walter Lindemann, MD, Eva Lengfelder, MD, Ullrich Graeven, Peter Staib, MD, Wolf-Dieter Ludwig, Harald Biersack, Yon-Dschun Ko, MD, Michael J. Uppenkamp, Stefan Korsten, Maike De Wit, Rudolf Peceny, MD, Tobias Gaska, MD, Xaver Schiel, Dirk M Behringer, MD, Michael G. Kiehl, MD, PhD, Bettina Zinngrebe, Gerald Meckenstock, Eva Roemer, Dirk Medgenberg, Ernst Spaeth-Schwalbe, MD, Birgit Braess, MD, Gero Massenkeil, MD, Heidrun Hindahl, Guido Trenn, Rainer Schwerdtfeger, MD, Susanne Amler, MSc, Cristina Sauerland, MSc, Andreas Faldum, MD, Michael Unterhalt, M.D. Ph.D., Stefan K. Bohlander, MD, Stephanie Schneider, PhD, Annika Dufour, PhD, Christian Buske, MD, Michael Fiegl, MD, Marion Subklewe, MD, Anja Baumgartner, PhD, Bernhard J. Woermann, MD, Dietrich Beelen, MD, Wolfgang Hiddemann, MD

Blood (2013) 122 (21): 619.

https://doi.org/10.1182/blood.V122.21.619.619

Published: 2013

Journal Articles

Rituximab Dose-Dense Chemotherapy Followed by Intensified High-Dose Chemotherapy and Autologous Stem Cell Transplantation (HDC+ASCT) Significantly Reduces the Risk of Progression Compared to Standard Rituximab Dose-Dense Chemotherapy As First Line Treatment in Young Patients with High-Risk (aa-IPI 2–3) Diffuse Large B-Cell Lymphoma (DLBCL): Final Results of Phase III Randomized Trial DLCL04 of the Fondazione Italiana Linfomi (FIL)

Blood (2012) 120 (21): 688.

https://doi.org/10.1182/blood.V120.21.688.688

Published: 2012

Journal Articles

Chronic Comorbidities and Chemotherapy-Induced Febrile Neutropenia in Patients with Non-Hodgkin Lymphoma

Chun Chao, PhD, John H Page, MD, ScD, Roberto Rodriguez, MD, Su-Jau Yang, PhD, Julie Huynh, MD, Victoria M Chia, PhD

Blood (2012) 120 (21): 3671.

https://doi.org/10.1182/blood.V120.21.3671.3671

Published: 2012

Journal Articles

Drug Resistance Gene Therapy to Augment Allogeneic Transplantation for the Treatment of Leukemia Following Relapse

Melanie Wurm, DVM, PhD, Nathaniel Williams, BS, Christina Ironside, BS, Brian C Beard, PhD, Hans-Peter Kiem, MD

Blood (2011) 118 (21): 2050.

https://doi.org/10.1182/blood.V118.21.2050.2050

Published: 2011

Journal Articles

Survival in Adolescents and Young Adults with Hodgkin Lymphoma Treated with Response-Based Chemotherapy on P9425 and P9426 Protocols: A Report From the Children's Oncology Group

Karen S. Fernández, MD, Lu Chen, PhD, Cindy Schwartz, MD, MPH, Allen R. Chauvenet, MD, PhD, Pedro A. de Alarcón, MD

Blood (2011) 118 (21): 91.

https://doi.org/10.1182/blood.V118.21.91.91

Published: 2011

Journal Articles

Tolerability of 2-Weekly CHOP+Rituximab Followed by Yttrium-90 Ibritumomab Tiuxetan (Zevalin) In Patients with Previously Untreated Diffuse Large B Cell Lymphoma (DLBCL): Final Analysis

Andrew Manson, Reem Karmali, MD, Irene Dehghan-Paz, MD, Eduardo Braun, MD, Teresa O'Brien, Stephanie A. Gregory, MD, Jamile M. Shammo, MD, Melissa L Larson, MD, Parmeswaran Venugopal, MD

Blood (2010) 116 (21): 4918.

https://doi.org/10.1182/blood.V116.21.4918.4918

Published: 2010

Journal Articles

Overall Survival of Lymphoma Patients In Randomized Controlled Trials Comparing Primary G-CSF Chemotherapy Support to Control.

Gary H. Lyman, MD, MPH, Jeffrey Crawford, Eva Culakova, PhD, MS, Marek S. Poniewierski, MD, MS, Mingyan Huang, Nicole M. Kuderer, MD, David C. Dale, MD

Blood (2010) 116 (21): 1502.

https://doi.org/10.1182/blood.V116.21.1502.1502

Published: 2010

Journal Articles

A Single Dose Filgastrim In the Treatment of Chemotherapy Induced Neutropenia

Kuppuswamy Jagarlamudi, MD, Meena Ahluwalia, MD, Jay Patel, MD, Arunbhai G. Patel, MD

Blood (2010) 116 (21): 4774.

https://doi.org/10.1182/blood.V116.21.4774.4774

Published: 2010

Journal Articles

Exon-Based Transcriptome Profiling Reveals Genes That Have Prognostic Impact on the Survival of Young High Risk Diffuse Large B-Cell/Follicular Grade 3 Lymphoma Patients Treated with Dose-Dense Chemoimmunotherapy and CNS Prophylaxis. Results From a Nordic Lymphoma Group Phase II Study

Satu Koivula, Minna Taskinen, Ping Chen, Harald Holte, Jan Delabie, Marja-Liisa Karjalainen-Lindsberg, Magnus Bjorkholm, Oystein Fluge, Lars Moller Pedersen, Mats Jerkeman, Mikael Eriksson, Sampsa Hautaniemi, Sirpa Leppa

Blood (2010) 116 (21): 3107.

https://doi.org/10.1182/blood.V116.21.3107.3107

Published: 2010

Journal Articles

Abbreviated, Dose Dense Fludarabine and Rituximab for Elderly Patients with Indolent B Cell Malignancies.

Gabriela Ballester, MD, Lisa Frazer, Pharm.D, Maria Tirona, MD, Oscar F Ballester, MD

Blood (2009) 114 (22): 4796.

https://doi.org/10.1182/blood.V114.22.4796.4796

Published: 2009

Journal Articles

Long-Term Outcome of 309 Young Patients Affected by Diffuse Large B-Cell Lymphoma (DLBCL) with a Poor-Prognosis at Diagnosis: a Pooled Analysis From Four Consecutive Trials of GIMURELL and Italian Lymphoma Intergroup (IIL).

Blood (2009) 114 (22): 2316.

https://doi.org/10.1182/blood.V114.22.2316.2316

Published: 2009

Journal Articles

Early 18 fluorodeoxyglucose PET Scan as a Prognostic Tool in Diffuse Large B-Cell Lymphoma Patients Treated with An Anthracycline-Based Chemotherapy Plus Rituximab.

Violaine Safar, Jehan Dupuis, Fabrice Jardin, Christophe Fruchart, Stéphane Bardet, Pierre Vera, Herve Tilly, Michel Meignan, Emmanuel Itti, Corinne Haioun

Blood (2009) 114 (22): 98.

https://doi.org/10.1182/blood.V114.22.98.98

Published: 2009

Journal Articles

A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425

Cindy L. Schwartz, Louis S. Constine, Doojduen Villaluna, Wendy B. London, Robert E. Hutchison, Richard Sposto, Steven E. Lipshultz, Charles S. Turner, Pedro A. deAlarcon, Allen Chauvenet

Blood (2009) 114 (10): 2051–2059.

https://doi.org/10.1182/blood-2008-10-184143

Published: 2009

Includes: Supplemental data

Journal Articles

Significant Expansion of Myeloid Derived Suppressor Cells in Patients with High- Risk Breast Cancer Treated with Dose Dense Adjuvant Chemotherapy

James E Talmadge, Elizabeth Reed, MD, Kenneth Cowan, Dmitry Gabrilovich, Phyllis Warkentin, William E. Janssen, PhD, James Wisecarver, James Anderson, Mary Mailliard, Sarah Maas, Orhan Turken, Uger Coskun

Blood (2008) 112 (11): 4653.

https://doi.org/10.1182/blood.V112.11.4653.4653

Published: 2008

NARROW

Health-Related Quality of Life (HRQL) Trajectories during Treatment for Advanced Stage Pediatric Hodgkin Lymphoma (HL)

Carfilzomib Weekly 20/56mg/m², Lenalidomide and Dexamethasone for Early Relapsed Refractory Multiple Myeloma

Comparison of Outcome of Adolescents with Newly Diagnosed Hodgkin Lymphoma (HL) in Argentina, Treated within a Pediatric Vs an Adults Clinical Trial : Experience of the Gatla Group

Long Term Follow-up of Adults with Burkitt's Lymphoma Receiving Dose-Dense Chemotherapy with or without Rituximab: A Single Center Retrospective 20 Years Study of 51 Patients

The Treatment of Primary Mediastinal Large B-Cell Lymphoma: A Two Decades Monocentric Experience on 98 Patients

High Efficacy and Significantly Shortened Neutropenia Of Dose-Dense S-HAM As Compared To Standard Double Induction: First Results Of a Prospective Randomized Trial (AML-CG 2008)

Chronic Comorbidities and Chemotherapy-Induced Febrile Neutropenia in Patients with Non-Hodgkin Lymphoma

Drug Resistance Gene Therapy to Augment Allogeneic Transplantation for the Treatment of Leukemia Following Relapse

Survival in Adolescents and Young Adults with Hodgkin Lymphoma Treated with Response-Based Chemotherapy on P9425 and P9426 Protocols: A Report From the Children's Oncology Group

Tolerability of 2-Weekly CHOP+Rituximab Followed by Yttrium-90 Ibritumomab Tiuxetan (Zevalin) In Patients with Previously Untreated Diffuse Large B Cell Lymphoma (DLBCL): Final Analysis

Overall Survival of Lymphoma Patients In Randomized Controlled Trials Comparing Primary G-CSF Chemotherapy Support to Control.

A Single Dose Filgastrim In the Treatment of Chemotherapy Induced Neutropenia

Exon-Based Transcriptome Profiling Reveals Genes That Have Prognostic Impact on the Survival of Young High Risk Diffuse Large B-Cell/Follicular Grade 3 Lymphoma Patients Treated with Dose-Dense Chemoimmunotherapy and CNS Prophylaxis. Results From a Nordic Lymphoma Group Phase II Study

Abbreviated, Dose Dense Fludarabine and Rituximab for Elderly Patients with Indolent B Cell Malignancies.

Long-Term Outcome of 309 Young Patients Affected by Diffuse Large B-Cell Lymphoma (DLBCL) with a Poor-Prognosis at Diagnosis: a Pooled Analysis From Four Consecutive Trials of GIMURELL and Italian Lymphoma Intergroup (IIL).

Early 18 fluorodeoxyglucose PET Scan as a Prognostic Tool in Diffuse Large B-Cell Lymphoma Patients Treated with An Anthracycline-Based Chemotherapy Plus Rituximab.

A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425

Significant Expansion of Myeloid Derived Suppressor Cells in Patients with High- Risk Breast Cancer Treated with Dose Dense Adjuvant Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only